EGFR and neoplasm: Specifically, patients diagnosed with left-sided tumors have appeared to have better responses with anti-EGFR therapy than with anti-VEGF therapy, with the bulk of tumor location subgroup analysis evidence coming from the available cetuximab-based phase 3 trials.